Skip to main content
. Author manuscript; available in PMC: 2017 Apr 1.
Published in final edited form as: Lancet Oncol. 2016 Mar 11;17(4):452–463. doi: 10.1016/S1470-2045(15)00614-2

Figure 1. Patient disposition.

Figure 1

Denominator used for a = 255, b = 246, c = 163, d = 83.

AE=adverse event. ALK=anaplastic lymphoma kinase. NSCLC=non-small-cell lung cancer.

* The total number of ALKi-pretreated and ALKi-naïve patients who discontinued treatment due to AEs were 18 and 8 patients, respectively. However, for one patient from each group, an AE was not considered the primary reason for discontinuation, and as such the number of patients listed in the patient disposition are 17 and 7, respectively.